Compare identical procurement scenarios, and keep clinic costs separate from patient and payer costs. Do not assume different medicines, doses, devices or formulations are clinically interchangeable.
What must every quotation specify?
Require:
- Product, presentation and package quantity.
- Dose-mix assumptions supplied by clinical leadership.
- Days of supply represented by each quoted unit.
- Introductory and continuing prices.
- Programme eligibility, fill limits and renewal conditions.
- Dispensing, shipping, supplies, payment-processing and platform fees.
- Failed-delivery, replacement, refund and cancellation treatment.
- Minimums, deposits, credit terms and unused-balance treatment.
- Who pays every charge.
- Price effective date, expiry and change mechanism.
What do current public cash prices illustrate?
The following are patient programme reference points observed in the reviewed pages—not wholesale quotes, negotiated clinic prices or guarantees of eligibility.
| Reference arrangement | Published price example | Procurement implication |
|---|---|---|
| Zepbound KwikPen through LillyDirect | Starting at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg under applicable terms | The page defines a month as 28 days; higher-dose pricing depends on refill timing; needle purchase is required |
| Wegovy injection through NovoCare's reviewed self-pay terms | $199 for qualifying introductory 0.25 mg/0.5 mg fills; standard offer $349 for 0.25–2.4 mg | Do not budget an introductory offer as the continuing price |
| Wegovy HD 7.2 mg through the same terms | $399 standard offer for a box of four pens | A different presentation/dose requires its own clinical and financial scenario |
Sources: LillyDirect Zepbound pricing; NovoCare programme terms. Lilly's reviewed page says regular prices apply when the relevant 45-day refill condition is not met. NovoCare's detailed introductory terms require the prescription to be written and received by December 31, 2026, and shipped by January 31, 2027. Recheck the complete terms at ordering. (lilly.com)
A four-week pack is not a calendar month. Thirteen 28-day packs cover 364 days. For illustration, 13 packs at an unchanged $349 would cost $4,537 before other expenses; that arithmetic is not a promise of future programme pricing or patient eligibility.
How should you define the comparison denominator?
Prefer cost per successfully fulfilled patient-period, not “cost per successfully treated patient.” Define the period and fulfilment criteria before analysing suppliers.
A proposed operational definition is:
A due patient-period is successfully fulfilled when the correct prescribed product and quantity reach the intended recipient within the agreed window, with no unresolved delivery or product exception at reporting close.
This measures fulfilment, not adherence, clinical benefit or treatment suitability. Report at least:
- Cost per enrolled patient-period.
- Cost per due patient-period.
- Cost per successfully fulfilled patient-period.
- Unfulfilled due periods, with reason and responsible owner.
For calendar-month reporting, use actual covered days and due dates rather than assuming one shipment equals one month.
What should the workbook calculate?
Use a separate worksheet for each clinically approved product/presentation scenario:
Clinic cost = clinic-paid medicine + clinic-paid fees + internal handling + unrecovered loss/credits + allocated implementation cost.
Patient cost = patient medicine payments + patient shipping/supply charges + separately disclosed care fees − actual patient refunds or credits.
Fulfilled-period unit cost = relevant cost numerator ÷ successfully fulfilled periods.
Do not count the same medicine payment twice when producing an across-payer view. Show refunds, replacements, unused inventory and timing differences explicitly.
What does a worked example look like?
Illustration only; none of these figures is a market benchmark. Assume a patient-dispensing arrangement, no clinic ownership of medicine, 1,000 patients with supply due in one 28-day period, and 950 successful fills. Assume only successful fills are charged.
| Item | Assumption/calculation | Amount |
|---|---|---|
| Patient medicine expenditure | 950 × $400 | $380,000 |
| Clinic platform fee | Assumed | $1,500 |
| Clinic exception-handling labour | 80 hours × $35 | $2,800 |
| Total clinic operating cost | $1,500 + $2,800 | $4,300 |
| Clinic cost per successful fill | $4,300 ÷ 950 | $4.53 |
| Combined measured expenditure per successful fill | $384,300 ÷ 950 | $404.53 |
| Unfulfilled due periods | 1,000 − 950 | 50 |
The $380,000 is not clinic revenue. The $404.53 figure excludes clinical-care costs and any unmodelled expenses. The 50 unfulfilled periods must remain visible; a lower aggregate medicine bill caused by failed access is not a procurement saving.
How do you model wastage and uncertainty?
For clinic-owned stock, use usable supply, not nominal drug content, and obtain pharmacist approval of the assumptions. An FDA letter dated August 12, 2026, highlighted compounded multidose vials containing more medication than patients could use within the relevant post-puncture period. That is a reason to examine presentation and discard assumptions—not permission to extend use to make the economics work. FDA letter reproduced by Arizona's Board of Nursing.
Run sensitivities for volume, dose mix, programme-price changes, delayed payment, failed delivery, staff handling and lost supplier capacity. Separately calculate maximum deposits, non-cancellable commitments and inventory exposure. Obtain actual quotes for credit, insurance and equipment rather than inserting supposed industry averages.
Stage 5 exit document: a finance-approved workbook showing continuing economics, uncertainty and who receives any potential savings.
Explore the table row by row
A working view of the research
Zepbound KwikPen through LillyDirect
- Published price example
- Starting at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg under applicable terms
- Procurement implication
- The page defines a month as 28 days; higher-dose pricing depends on refill timing; needle purchase is required
Answers stay in this session unless you choose to save. No account needed.
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/zepbound
- novocare.com · Source 2 ↗https://www.novocare.com/eligibility/obesity-delivery.html
- azbn.gov · Source 3 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials